+91 789 2456 581 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Pharma News

Keep updating your pharma knowledge

24 Sep 2017

What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval

/

Posted Byadmin

/

Comments0

/

TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval

Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively.

Related Articles

Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
Quick look into Roche’s Tecentriq US FDA priority review grant
USFDA approved first drug for spinal muscular atrophy
Kite Pharma’s axicabtagene got US FDA priority review status to treat NHL
USFDA approved new drug Rubraca, rucaparib

European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)

USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers

About Post Author

admin

Leave a Reply Cancel Reply

Search With Term

Recent Industry Update

Pharma Disinvestment deal: AstraZeneca to divest Synagis US rights to Sobi
Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
Insight on Strides – SUDA Pharma Strategic Deal
How much is the ideal royalty payment in pharmaceutical industry?
Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK’s Breo Ellipta generics
Pharma acquisition Insight: Hikma Pharmaceuticals to acquire Medlac Pharma
Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
Glenmark’s anti-myeloma drug to start phase 1 trial in solid tumors
Glenmark’S Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Pfizer gets US FDA approval for Lorbrena for previously-treated ALK-positive metastatic NSCLC
Quick Look in Unichem – Optimus deal
Novartis R&D portfolio update
US FDA grants marketing approval for Fluobeam 800 & PTeye System
Bristol-Myers Squibb, Infinity Pharma ink clinical collaboration deal
Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
Case Study: USFDA The Limited Population Pathway and approval of Arikayce
Dr. Reddy’s sells Cloderm cream to EPI Health
DRL to disinvest antibiotics plant to Abu Dhabi-based Neopharma
Case Study: Product Recall due to labeling error
Tildrakizumab (Ilumetri): Discovery, Development to Commercialization Case Study
Consequences and progress of Takeda-Shire Buyout
Indian health ministry banned 329 controversial fixed dose combination with immediate effect
Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
Market Launch and brand positioning of Volini Maxx
Grünenthal’s Duzallo: EU marketing authorization and Brand Positining
USFDA approval of patisiran, first-of-its kind targeted RNA-based therapy
Digital Strategy for pharma brand promotion: Merck launch map4health
Insight on Novo Nordisk’s acquisition of Bristol, UK-based Ziylo for $800 million

Monthly Archieves

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query / Feedback

First Name

Last Name

Email Address

Your Query *

Write Here

10 plus 4 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.